|
|
Vol. 11.47 – 01 December, 2022
|
|
|
|
|
|
|
|
Investigators systemically analyzed lung pathogenesis in SARS-CoV-2- and its delta variant-infected humanized CD147 transgenic mice. Histopathology and transmission electron microscopy revealed inflammation, fibroblast expansion, and pronounced fibrotic remodeling in SARS-CoV-2-infected lungs. [Signal Transduction and Targeted Therapy]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
Researchers investigated whether melatonin could protect against sepsis-induced acute lung injury and lipopolysaccharide-treated lung epithelial cells through mitochondrial quality control as well as its possible molecular targets. [Cellular and Molecular Life Sciences]
|
|
|
|
|
|
The authors examined mitochondrial citrate accumulation in alveolar epithelial cells that were challenged with lipopolysaccharide ex vivo and in vivo. [Experimental & Molecular Medicine]
|
|
|
|
|
|
Investigators evaluated the anti-fibrotic efficacy of the proton pump inhibitor esomeprazole when combined with pirfenidone in vitro and in vivo.
[Scientific Reports]
|
|
|
|
|
|
The protein kinase C-alpha (PRKCA)/miR-15a-5p/PDK4 axis alleviated acute lung injury caused by sepsis by promoting mitophagy and repressing anti-inflammatory response both in vivo and in vitro. [Infection and Immunity]
|
|
|
|
|
|
|
|
Scientists showed that NF-κB acted as a transcriptional repressor in the suppression of GPRC5A. NF-κB induced GPRC5A repression both in vitro and in vivo. [JCI Insight]
|
|
|
|
|
|
Researchers found that cleavage and polyadenylation specific factor 6 (CPSF6) was significantly higher expressed in tumor tissues than in normal tissues in multiple cancer types.
[Aging]
|
|
|
|
|
|
Investigators found that JQ1, a bromodomain and extra terminal domain (BET) inhibitor, suppressed NSCLC cell growth, reduced the Met expression, and contributed to inactivation of PI3K/Akt and MAPK/ERK pathways.
[Cell Biology International]
|
|
|
|
|
|
Researchers revealed the clinical significance of the N6-methyladenosine (m6A) RNA modification atlas, the function, and molecular targets CSF1R of METTL14 in NSCLC cell lines. [Thoracic Cancer]
|
|
|
|
|
|
|
|
The authors describe the biological functions of SMARCA4 and its role in NSCLC development, metastasis, functional epigenetics, and potential therapeutic approaches for NSCLCs with SMARCA4 alterations. [Cancer Letters]
|
|
|
|
|
|
|
|
Aridis Pharmaceuticals, Inc. announced the closing of patient enrollment in the multiple ascending doses and dose-ranging cohorts in the Phase IIa clinical trial of AR-501 in cystic fibrosis patients. [Aridis Pharmaceuticals, Inc. (Globe Newswire)]
|
|
|
|
|
|
|
|
January 22 – 25, 2023 Santa Fe, New Mexico, United States
|
|
|
|
|
|
|
|
|
|
|
University of Utah – Salt Lake City, Utah, United States
|
|
|
|
|
|
|
University of Kansas Medical Center – Kansas City, Kansas, United States
|
|
|
|
|
|
|
Cedars Sinai Medical Centre – Los Angeles, California, United States
|
|
|
|
|
|
|
Charite – University Medicine Berlin – Berlin, Germany
|
|
|
|
|
|
|
STEMCELL Technologies, Inc. – Boston, Massachusetts, United States
|
|
|
|
|
|